Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sanofi (SNYNF) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Sanofi (SNYNF) over the last 17 years, with Q4 2025 value amounting to -$655.4 million.

  • Sanofi's Interest Expenses rose 4283.84% to -$655.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year increase of 1567.53%. This contributed to the annual value of -$636.2 million for FY2025, which is 4521.48% up from last year.
  • As of Q4 2025, Sanofi's Interest Expenses stood at -$655.4 million, which was up 4283.84% from -$687.4 million recorded in Q3 2025.
  • Over the past 5 years, Sanofi's Interest Expenses peaked at -$98.8 million during Q1 2022, and registered a low of -$1.4 billion during Q4 2023.
  • In the last 5 years, Sanofi's Interest Expenses had a median value of -$222.0 million in 2023 and averaged -$356.2 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 459637.29% in 2021, then skyrocketed by 5369.98% in 2025.
  • Quarter analysis of 5 years shows Sanofi's Interest Expenses stood at -$106.4 million in 2021, then tumbled by 321.95% to -$448.9 million in 2022, then tumbled by 209.9% to -$1.4 billion in 2023, then rose by 17.58% to -$1.1 billion in 2024, then skyrocketed by 42.84% to -$655.4 million in 2025.
  • Its Interest Expenses stands at -$655.4 million for Q4 2025, versus -$687.4 million for Q3 2025 and -$167.5 million for Q2 2025.